It isn't, and I won't overclaim it," said Anant Vinjamoori, chief medical officer of telehealth provider Hims & Hers
These findings emphasize the importance of verified sources for any injectable product
Mehta, MD, Laura D
Changes in BMI and Fat Mass GLP-1 RAs (e.g., liraglutide, semaglutide, exenatide) consistently reduce BMI and fat mass in T2D patients, primarily through appetite suppression and delayed gastric emptying [12, 13, 31]
With treatment, lifestyle changes, or therapy, some men eventually no longer need it
This medication was originally approved for type 2 diabetes to improve blood sugar control, but its appetite-modulating properties also support weight loss under medical supervision